Samir Vattompadam brings deep cross-functional experience that spans commercial and clinical development, global-US-affiliate based roles, and small, medium, and large organizations across the pharmaceutical and biotech industry. Before joining Vor Bio, Samir served as Vice President, Program Executive for EQRx where he led cross-functional program strategy teams for lead candidates in immuno-oncology from late-stage studies through to regulatory submissions, including the company’s first marketing authorization applications to the MHRA and EMA for Sugemalimab in metastatic non-small cell lung cancer. Prior to EQRx, he was Executive Director, Product Team Leader at Seagen for several late-stage ADCs including TIVDAK, PADCEV, and ADCETRIS. Samir led cross-functional teams focusing on the development, submission, and approval for TIVDAK in metastatic cervical cancer. Earlier in his career, Samir served at Roche in various roles including the Global Commercial Director for GU cancers for TECENTRIQ (atezolizumab), Global Product Manager for GAZYVA (obinutuzumab) in lymphomas, and roles spanning oncology marketing, sales, and medical affairs at Roche Canada. Samir holds a Masters in Medical Sciences and a Bachelor of Science in Biology from McMaster University.
Samir Vattompadam, MS
